Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Grimaldi

Showing results (401-410 of 410) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 410 results.
Oncoimmunology|March 28, 2017
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patientsRossana Tallerico, Costanza M Cristiani, Elina Staaf, et al.
Cancer Immunology Research|April 4, 2019
Accumulation of Circulating CCR7<sup>+</sup> Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic PathwayCostanza Maria Cristiani, Alice Turdo, Valeria Ventura, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 23, 2014
Storytelling and story testing in domesticationPascale Gerbault, Robin G Allaby, Nicole Boivin, et al.
Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
Reumatismo|March 25, 2024
Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in ItalyA Fassio, G Porciello, G Carioli, et al.
NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
Pageof 41

Showing results (401-410 of 410) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 410 results.
Oncoimmunology|March 28, 2017
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patientsRossana Tallerico, Costanza M Cristiani, Elina Staaf, et al.
Cancer Immunology Research|April 4, 2019
Accumulation of Circulating CCR7<sup>+</sup> Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic PathwayCostanza Maria Cristiani, Alice Turdo, Valeria Ventura, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 23, 2014
Storytelling and story testing in domesticationPascale Gerbault, Robin G Allaby, Nicole Boivin, et al.
Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
Reumatismo|March 25, 2024
Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in ItalyA Fassio, G Porciello, G Carioli, et al.
NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
Pageof 41